These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33943000)

  • 41. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.
    Orrell C; Walensky RP; Losina E; Pitt J; Freedberg KA; Wood R
    Antivir Ther; 2009; 14(4):523-31. PubMed ID: 19578237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High prevalence of virological failure and HIV drug mutations in a first-line cohort of Malawian children.
    Huibers MHW; Moons P; Cornelissen M; Zorgdrager F; Maseko N; Gushu MB; Iwajomo OH; Boele van Hensbroek M; Calis JCJ
    J Antimicrob Chemother; 2018 Dec; 73(12):3471-3475. PubMed ID: 30169653
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
    Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK
    J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.
    Barennes H; Guillet S; Limsreng S; Him S; Nouhin J; Hak C; Srun C; Viretto G; Ouk V; Delfraissy JF; Ségéral O
    PLoS One; 2014; 9(8):e105736. PubMed ID: 25166019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL).
    O'Halloran C; Gilleece Y; Leung S; Canuto V; McAlpine C; Ross S; Norcross C; Gaffney S; Siani N; Hickey W; Moore A; Rajkovic-Hooley O; Milinkovic A
    Int J STD AIDS; 2024 Mar; 35(3):206-216. PubMed ID: 37970812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.
    Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos RD
    Lancet HIV; 2023 Nov; 10(11):e733-e741. PubMed ID: 37832567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
    Rhee SY; Blanco JL; Jordan MR; Taylor J; Lemey P; Varghese V; Hamers RL; Bertagnolio S; Rinke de Wit TF; Aghokeng AF; Albert J; Avi R; Avila-Rios S; Bessong PO; Brooks JI; Boucher CA; Brumme ZL; Busch MP; Bussmann H; Chaix ML; Chin BS; D'Aquin TT; De Gascun CF; Derache A; Descamps D; Deshpande AK; Djoko CF; Eshleman SH; Fleury H; Frange P; Fujisaki S; Harrigan PR; Hattori J; Holguin A; Hunt GM; Ichimura H; Kaleebu P; Katzenstein D; Kiertiburanakul S; Kim JH; Kim SS; Li Y; Lutsar I; Morris L; Ndembi N; Ng KP; Paranjape RS; Peeters M; Poljak M; Price MA; Ragonnet-Cronin ML; Reyes-Terán G; Rolland M; Sirivichayakul S; Smith DM; Soares MA; Soriano VV; Ssemwanga D; Stanojevic M; Stefani MA; Sugiura W; Sungkanuparph S; Tanuri A; Tee KK; Truong HM; van de Vijver DA; Vidal N; Yang C; Yang R; Yebra G; Ioannidis JP; Vandamme AM; Shafer RW
    PLoS Med; 2015 Apr; 12(4):e1001810. PubMed ID: 25849352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru.
    Trebelcock WL; Lama JR; Duerr A; Sanchez H; Cabello R; Gilada T; Segura P; Reisner SL; Mayer KH; Mullins J; Bender Ignacio RA
    J Int AIDS Soc; 2019 Nov; 22(11):e25411. PubMed ID: 31773888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
    Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
    Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
    Meriki HD; Tufon KA; Anong DN; Atanga PN; Anyangwe IA; Cho-Ngwa F; Nkuo-Akenji T
    PLoS One; 2019; 14(11):e0225575. PubMed ID: 31751428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-naïve Ugandan children.
    Soeria-Atmadja S; Amuge P; Nanzigu S; Bbuye D; Rubin J; Eriksen J; Kekitiinwa A; Obua C; Gustafsson LL; Navér L
    Acta Paediatr; 2020 Dec; 109(12):2706-2716. PubMed ID: 32304595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.
    Boerma RS; Boender TS; Sigaloff KC; Rinke de Wit TF; van Hensbroek MB; Ndembi N; Adeyemo T; Temiye EO; Osibogun A; Ondoa P; Calis JC; Akanmu AS
    J Int AIDS Soc; 2016; 19(1):21140. PubMed ID: 27836020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
    Lai MT; Feng M; Xu M; Ngo W; Diamond TL; Hwang C; Grobler JA; Hazuda DJ; Asante-Appiah E
    Antimicrob Agents Chemother; 2022 May; 66(5):e0222321. PubMed ID: 35491829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.
    Aghokeng AF; Kouanfack C; Laurent C; Ebong E; Atem-Tambe A; Butel C; Montavon C; Mpoudi-Ngole E; Delaporte E; Peeters M
    AIDS; 2011 Nov; 25(17):2183-8. PubMed ID: 21860346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naive HIV-infected Children in Mali.
    Crowell CS; Maiga AI; Sylla M; Taiwo B; Kone N; Oron AP; Murphy RL; Marcelin AG; Traore B; Fofana DB; Peytavin G; Chadwick EG
    Pediatr Infect Dis J; 2017 Nov; 36(11):e258-e263. PubMed ID: 28198788
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
    Rhee SY; Jordan MR; Raizes E; Chua A; Parkin N; Kantor R; Van Zyl GU; Mukui I; Hosseinipour MC; Frenkel LM; Ndembi N; Hamers RL; Rinke de Wit TF; Wallis CL; Gupta RK; Fokam J; Zeh C; Schapiro JM; Carmona S; Katzenstein D; Tang M; Aghokeng AF; De Oliveira T; Wensing AM; Gallant JE; Wainberg MA; Richman DD; Fitzgibbon JE; Schito M; Bertagnolio S; Yang C; Shafer RW
    PLoS One; 2015; 10(12):e0145772. PubMed ID: 26717411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon.
    Fokam J; Takou D; Teto G; Nforbih SE; Kome OP; Santoro MM; Ngoufack ES; Eyongetah M; Palmer D; Fokunang ET; Fokunang CN; Colizzi V; Perno CF; Ndjolo A
    PLoS One; 2020; 15(7):e0235958. PubMed ID: 32692778
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of HIV-1 drug resistance among patients failing first-line antiretroviral therapy in Ethiopia.
    Getaneh Y; He Q; Rashid A; Kassa D; Kang L; Yi F; Liao L; Shao Y
    J Glob Antimicrob Resist; 2022 Sep; 30():418-427. PubMed ID: 35917929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.